Pharvaris N.V. (PHVS)


+0.05 (+0.27%)
Symbol PHVS
Price $18.55
Beta -3.816
Volume Avg. 0.05M
Market Cap 757.894M
Shares () -
52 Week Range 1.77-26.86
1y Target Est -
DCF Unlevered PHVS DCF ->
DCF Levered PHVS LDCF ->
ROE -43.67% Strong Sell
ROA -36.67% Strong Sell
Operating Margin -
Debt / Equity 0.19% Neutral
P/E -7.96 Strong Sell
P/B 4.16 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest PHVS news

Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA
NASDAQ Global Select

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.